This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
McKesson (MCK) Stock Pares Gains Following Rx Savings Buyout
by Zacks Equity Research
McKesson (MCK) agrees to buy privately-held Rx Savings Solutions in alignment with its strategic plan of creating accessible and affordable treatment options.
Here's Why You Should Retain Stryker (SYK) Stock For Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.
Zimmer Biomet (ZBH) to Offer New Shoulder Replacement System
by Zacks Equity Research
Zimmer Biomet (ZBH) gets FDA nod for the Identity Shoulder System to help surgeons perform anatomic, reverse and revision shoulder replacement with precision.
Abiomed (ABMD) Posts Impellas Positive Study Results in Japan
by Zacks Equity Research
Abiomed's (ABMD) latest multi-center, multi-society study of Impella-supported patients is expected to significantly improve patient outcomes.
3 Reasons to Retain PacBio (PACB) Stock in Your Portfolio
by Zacks Equity Research
PacBio's (PACB) strength in its Sequel system raises optimism about the stock.
Should You Invest in the First Trust Consumer Staples AlphaDEX ETF (FXG)?
by Zacks Equity Research
Sector ETF report for FXG
McKesson (MCK) Stock Moves -0.97%: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed the most recent trading day at $345.56, moving -0.97% from the previous trading session.
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vinci Surgical System. Higher production costs are a woe.
Quest Diagnostics (DGX) to Offer Lab Services for Lee Health
by Zacks Equity Research
Quest Diagnostics (DGX) inked a new agreement to deliver high-quality diagnostics services for a renowned healthcare provider in Southwest Florida.
Here's Why You Should Retain Boston Scientific (BSX) For Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) impressive top-line results and notable acquisitions.
Inari Medical (NARI) Posts Positive Results of FLASH Registry
by Zacks Equity Research
Inari Medical's (NARI) FlowTriever's latest favorable results are expected to significantly improve the treatment of PE.
Neogen (NEOG) Launches Test for Detection of Cashew Allergen
by Zacks Equity Research
Neogen's (NEOG) new quantitative test shows a high level of specificity to very low levels of cashew protein (down to 0.2 ppm).
Exact Sciences (EXAS) Cologuard Business Grows Amid Cost Woes
by Zacks Equity Research
Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.
The Zacks Analyst Blog Highlights Corteva, Hershey, National Fuel Gas and McKesson
by Zacks Equity Research
Corteva, Hershey, National Fuel Gas and McKesson are included in this Analyst Blog.
Defense Wins Ballgames; 3 Blue-Chip Stocks To Consider
by Derek Lewis
Due to their well-established nature and track records of success, these companies are positioned to weather a dark fiscal cloud better than most.
QIAGEN (QGEN) Assays to Detect Organ Transplant-Related Viruses
by Zacks Equity Research
QIAGEN's (QGEN) latest additions to the NeuMoDx assay menu will help identify EBV and HHV-6 viruses in immunocompromised patients.
3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
Teleflex (TFX) Witnesses Lower UroLift Sales, Cost Woes
by Zacks Equity Research
Teleflex's (TFX) lowered revenue and adjusted EPS outlook for 2022 indicates lackluster performance, which increases investors' concern.
Abiomed's (ABMD) Impella-Related Research Gets FDA Clearance
by Zacks Equity Research
Abiomed's (ABMD) latest regulatory clearances for clinical research of Impella heart pumps in AMI cardiogenic shock patients are expected to significantly improve patient outcomes.
3 Reasons to Hold Catalent (CTLT) Stock in Your Portfolio
by Zacks Equity Research
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism about the stock.
Beat the Market Vagaries With 4 Top-Ranked Defensive Bets
by Snehadri Nag
Grab these four defensive stocks, namely Corteva (CTVA), Hershey (HSY), National Fuel Gas Company (NFG) and McKesson (MCK), which hold strong potential.
Is SPDR Russell 1000 Momentum Focus ETF (ONEO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for ONEO
3 Reasons to Hold Insulet (PODD) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Insulet (PODD) on Omnipod's continued market access expansion.
Here's Why Investors Should Retain Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra's (IART) better-than-expected results and the continued demand for its products.
Tandem Diabetes (TNDM) Faces Expense Woes, Macro Issues
by Zacks Equity Research
Factoring in the pandemic and competitive pressure as well as evolving economic environment, including inflation and the threat of recession, Tandem Diabetes (TNDM) slashes full-year guidance.